Stock Analysis
Tianda Pharmaceuticals Reports First Half 2024 Earnings
Tianda Pharmaceuticals (HKG:455) First Half 2024 Results
Key Financial Results
- Net loss: HK$27.2m (flat on 1H 2023).
- HK$0.013 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tianda Pharmaceuticals shares are down 12% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Tianda Pharmaceuticals (1 doesn't sit too well with us) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Tianda Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:455
Tianda Pharmaceuticals
Engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.